ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.5300
+0.1700 (+7.20%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close2.3600
Open2.3500
Bid2.5200 x 0
Ask2.5300 x 0
Day's Range2.3500 - 2.5700
52 Week Range2.2000 - 10.6500
Volume59,593
Avg. Volume31,435
Market Cap51.355M
Beta (3Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-1.0250
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.81
  • ACCESSWIRE8 days ago

    Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 16, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting additional immune-based biomarker data used to help predict patient response to pelareorep in combination with checkpoint inhibitor therapy. The abstract was published online as part of the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in the Meeting Proceedings, an online supplement of ASCO's Journal of Clinical Oncology. The abstract, titled, "Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC)," describes further immune analysis of the peripheral blood of patients from REO 024, a completed phase 1b study of pelareorep and Keytruda® (pembrolizumab) in combination with chemotherapy in patients with advanced (second-line) pancreatic cancer.

  • ACCESSWIRE21 days ago

    Oncolytics Biotech (R) Reports 2019 First Quarter Financial Results and Operational Highlights

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2019. ''Our primary focus remains the breast cancer program and the timely completion of our AWARE-1 study of pelareorep in combination with the immune checkpoint inhibitor Tecentriq.

  • ACCESSWIRE21 days ago

    Oncolytics Biotech(R) Announces Voting Results from the Annual General Meeting of Shareholders

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / May 3, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRElast month

    Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE2 months ago

    Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 8, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient has been treated in the AWARE-1 window of opportunity (WOO) study that is being conducted in collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. Patients will receive the appropriate intervention for their breast cancer sub-type, plus pelareorep, with or without Tecentriq® (atezolizumab), followed by surgery. "We are pleased to have treated the first patient in our window of opportunity study that will yield important results confirming both our recently identified biomarker and pelareorep's ability to prime an antitumor immune response," said Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.

  • ACCESSWIRE2 months ago

    Oncolytics Biotech(R) to Host Key Opinion Leader Meeting on the Emerging Role of Biomarkers and Oncolytic Viruses in the Treatment of Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a Key Opinion Leader meeting to discuss the emerging role of biomarkers and oncolytic viruses in the treatment of cancer on Thursday, April 11, 2019 at 12 pm EDT in New York City. The event will feature presentations by company management and Key Opinion Leader Dirk Arnold MD, PhD, Executive Board Member of the European Society of Medical Oncology (ESMO) & Chief of Oncology at Asklepios Klinik Altona, who will discuss biomarkers, their importance in trials, their influence on large pharma and their impact in both clinical and commercial settings, as well as recent biomarker data from Oncolytics.

  • ACCESSWIRE2 months ago

    Oncolytics Biotech(R) to Present at the 18th Annual Needham Healthcare Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 3, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE2 months ago

    Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 which is taking place March 30 through April 3 in Atlanta, Georgia.

  • ACCESSWIRE2 months ago

    Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / March 28, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an article highlighting the synergistic effect of oncolytic immunotherapy in combination with a proteasome inhibitor in the treatment of multiple myeloma. The article, entitled, "Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model," co-authored by Oncolytics' President and Chief Executive Officer, Dr. Matt Coffey was published in the March 12 edition of Blood Advances. The article demonstrates that the combination of reovirus and bortezomib can overcome drug resistance, a major hurdle in the treatment of multiple myeloma.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ONC.TO earnings conference call or presentation 8-Mar-19 1:30pm GMT

    Full Year 2018 Oncolytics Biotech Inc Earnings Call

  • ACCESSWIRE3 months ago

    Oncolytics Biotech (R) Announces 2018 Year-End Results and Operational Highlights

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / March 8, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter and year ended December 31, 2018. ''With a growing number of large pharma collaborations, continued advancement with our registration program in metastatic breast cancer and recently announced biomarker data, we have made tremendous progress in a short period of time,'' said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

  • ACCESSWIRE3 months ago

    Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights

    CALGARY, AB and SAN DIEGO, CA / March 1, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Friday, March 8, 2019 following release of its year end 2018 financial results. Overseas callers should contact investor relations for the toll-free dial information for their country. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.

  • ACCESSWIRE3 months ago

    Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 27, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract demonstrating a biomarker for predicting clinical response in patients treated with pelareorep. Detailed results will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place March 30 through April 3 in Atlanta, Georgia. ''With a simple blood draw, this biomarker data allows physicians to understand which patients are likely to respond to treatment, allowing for the design of clinical studies that are cheaper, faster and more likely to succeed,'' said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

  • ACCESSWIRE3 months ago

    Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 11, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the Spanish Agency for Medicine and Health Products has granted final approval for the forthcoming AWARE-1 window of opportunity study in breast cancer. This study, which represents the first application of Oncolytics' master clinical supply agreement with Roche for the combination of pelareorep with a leading immune checkpoint inhibitor atezolizumab (Tecentriq®), is a precursor to Oncolytics' previously announced phase 3 breast cancer study and will add to the company's growing critical mass of biomarker data.

  • ACCESSWIRE4 months ago

    Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 21st Annual BIO CEO & Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 2:30 pm ET, on Monday, February 11, 2019, in the Herald/Soho Room at the New York Marriott Marquis. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Oncolytics Biotech, Delivra, Aptose Biosciences and ProMIS Neurosciences

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire5 months ago

    Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients. This study is based on findings from the NCI 9603 multiple myeloma study that combined pelareorep with carfilzomib that resulted in objective responses, elimination of multiple myeloma cells and most importantly, an inflamed phenotype with PD-L1 overexpression. “Having worked with pelareorep in multiple myeloma and understanding its ability to act as a potentiator of checkpoint blockade, I’m very excited to work with the Oncolytics team on this study,” said Dr. Craig Hofmeister, Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine.

  • ACCESSWIRE5 months ago

    Today's Research Reports on IntelliPharmaCeutics International, Centric Health, Knight Therapeutics and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of ONC.TO earnings conference call or presentation 12-Nov-18 1:30pm GMT

    Q3 2018 Oncolytics Biotech Inc Earnings Call

  • GlobeNewswire6 months ago

    Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a poster presentation made at the American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 1-4 in San Diego, California.  The poster highlights pelareorep’s ability to increase PD-L1 expression on tumor cells in patients with relapsed myeloma. The poster, authored by Craig C. Hofmeister, Acting Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine, et al., is titled “Oncolytics Virus Replication Using Pelareorep and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses”, was presented yesterday.

  • GlobeNewswire6 months ago

    Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as Chief Medical Officer.  Dr. Laeufle will oversee the clinical development plan for pelareorep as the company drives towards a registration study in breast cancer. “Dr. Laeufle brings a tremendous track record in clinical advancement to Oncolytics, including an approval in the treatment of metastatic breast cancer,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...

  • GlobeNewswire6 months ago

    Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 2 study combining pelareorep with Merck’s Keytruda® to treat advanced pancreatic adenocarcinoma. “We are very excited to start enrollment in this combination study which expands upon our findings from an earlier Keytruda study in advanced pancreatic cancer,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. “REO 024, our previous phase 1b study with Keytruda, showed objective response, long-term stabilization of disease and promotion of an inflamed phenotype in second line pancreatic cancer patients.

  • GlobeNewswire6 months ago

    Oncolytics Biotech® Announces Attendance of Upcoming Conferences

    CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered.

  • GlobeNewswire6 months ago

    Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

    - Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host.